SCHEMBL15020544

SCHEMBL15020544

CCn1nc(-c2cccnc2)cc1-c1cnc2[nH]c(C3CCCCC3)cc2c1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NPY5R Q15761 1/20 0.43
PIM1 P11309 1/20 0.37
CYP2E1 P05181 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2A6 P11509 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2B6 P20813 1/20 0.37
CYP2C19 P33261 1/20 0.37
CHEK1 O14757 1/20 0.37
ACHE P22303 1/20 0.37
CDK9 P50750 4/20 0.37
CRHR1 P34998 1/20 0.36
CRHR2 Q13324 1/20 0.36
CCNT1 O60563 1/20 0.36
DRD2 P14416 1/20 0.36
DRD4 P21917 1/20 0.36
MET P08581 2/20 0.35
ULK1 O75385 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15020474 0.87 CHEK1 (0.35) NPY5RCHEK1ACHECDK9CCNT1
SCHEMBL15020547 0.81 BRD4 (0.43) NPY5RCYP2E1CYP3A4CYP2A6CYP2C9
SCHEMBL15020878 0.79 CYP19A1 (0.40) NPY5RCYP2E1CYP3A4CYP2A6CYP2C9
SCHEMBL15020659 0.78 BRD4 (0.53) CYP2E1CYP3A4CYP2A6CYP2C9CYP2B6
SCHEMBL15020516 0.77 ORAI1 (0.41) CYP2E1CYP3A4CYP2A6CYP2C9CYP2B6
SCHEMBL15036344 0.77 CLK2 (0.38) NPY5RCYP2E1CYP3A4CYP2A6CYP2C9
SCHEMBL15020674 0.76 CYP2E1 (0.37) NPY5RCYP2E1CYP3A4CYP2A6CYP2C9
SCHEMBL15020476 0.71 BRD4 (0.43) PIM1ULK1
SCHEMBL26686471 0.68 NPY5R (0.48) NPY5RCDK9CCNT1
SCHEMBL18642566 0.67 CYP2A6 (0.54) CYP2E1CYP3A4CYP2A6CYP2C9CYP2B6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2013092467-A1 7-AZAINDOLE INHIBITORS OF CRAC F. HOFFMANN-LA ROCHE AG (CH) 2013-06-27 WO claimed
US-20130158049-A1 7-AZAINDOLE INHIBITORS OF CRAC HOFFMANN-LA ROCHE INC. (US) 2013-06-20 US claimed
WO-2013092467-A1 7-AZAINDOLE INHIBITORS OF CRAC F. HOFFMANN-LA ROCHE AG (CH) 2013-06-27 WO disclosed
WO-2013092467-A1 7-AZAINDOLE INHIBITORS OF CRAC F. HOFFMANN-LA ROCHE AG (CH) 2013-06-27 WO disclosed
US-20130158049-A1 7-AZAINDOLE INHIBITORS OF CRAC HOFFMANN-LA ROCHE INC. (US) 2013-06-20 US disclosed
US-20130158049-A1 7-AZAINDOLE INHIBITORS OF CRAC HOFFMANN-LA ROCHE INC. (US) 2013-06-20 US disclosed
US-20130158049-A1 7-AZAINDOLE INHIBITORS OF CRAC HOFFMANN-LA ROCHE INC. (US) 2013-06-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158049-A1 7-AZAINDOLE INHIBITORS OF CRAC ORAI1, CACNA1I, RYR2 NPY5R 1236/4885PIM1 3946/4885CYP2E1 2034/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.